CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Why are Pharmaceutical Companies Turning to CROs?

Life Sciences Review | Friday, June 18, 2021
Tweet

CROs are helping to compensate for the pharmaceutical industry's lack of innovation. With a commitment to the highest performance standards, accuracy, and efficiency, many of them constantly develop and enhance technologies to provide sample analysis, assay validation, and lot release testing before manufacture.


FREMONT, CA: Over several decades, the CRO industry has evolved. It took shape in the mid-twentieth century with companies that supplied basic animal experimentation services. As regulatory frameworks arose in the 1970s and 1980s, contract research firms moved into clinical studies. There are presently over 1,000 CROs in operation, with only a few serving the global market.


It might take years to bring a drug product to market, from research through final drug approval. The average cost of developing a single new treatment is 2.6 billion dollars, including the cost of failures. The risk is substantial, given that only 12 percent of novel treatment candidates in clinical trials are ultimately approved by the US Food and Drug Administration (FDA). Pharmaceutical companies are turning to contract research groups to:


Reduce Expenses: Outsourcing is primarily a risk-reduction approach. Profits at pharmaceutical businesses have fallen dramatically in recent years. Working with a CRO offers various advantages, including decreasing or eliminating the need to engage research workers, invest in in-house infrastructure for R&D and manufacturing, and manage an unclear success potential. It has the potential to improve success rates and speed up drug discovery and development, potentially leading to higher profitability.


Handle Drugs and Clinical Trials That Are Getting More Complex: Drug development has become more difficult due to advances in cell and gene therapies, antibody-drug conjugates, cytotoxic chemical products, and in vitro and in vivo processing procedures. CROs are helping to compensate for the pharmaceutical industry's lack of innovation. With a commitment to the highest performance standards, accuracy, and efficiency, many of them constantly develop and enhance technologies to provide sample analysis, assay validation, and lot release testing before manufacture.


Decrease Time to Market: CROs already have the skills and infrastructure in place to perform vital services more efficiently. They can make real-time changes to drug candidates depending on data received during clinical trials. As various complexities are addressed at every step of development by an organization built on services that address these, shorter lead times allow pharmaceutical enterprises to realize a return on their products much sooner.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/why-are-pharmaceutical-companies-turning-to-cros-nwid-405.html